These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 22623641)

  • 1. IVF is cost effective up to age 43, says NICE.
    Kmietowicz Z
    BMJ; 2012 May; 344():e3656. PubMed ID: 22623641
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of in vitro fertilization.
    Collins J
    Semin Reprod Med; 2001 Sep; 19(3):279-89. PubMed ID: 11679909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost analysis of shared oocyte in vitro fertilization.
    Peskin BD; Austin C; Lisbona H; Goldfarb JM
    Obstet Gynecol; 1996 Sep; 88(3):428-30. PubMed ID: 8752253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Money in--babies out: assessing the long-term economic impact of IVF-conceived children.
    Connolly M; Hoorens S; Ledger W
    J Med Ethics; 2008 Sep; 34(9):653-4. PubMed ID: 18757633
    [No Abstract]   [Full Text] [Related]  

  • 5. Laparoscopic tubal reanastomosis versus in vitro fertilization: cost-based decision analysis.
    Hirshfeld-Cytron J; Winter J
    Am J Obstet Gynecol; 2013 Jul; 209(1):56.e1-6. PubMed ID: 23583214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The right to try.
    Pearce L
    Nurs Stand; 2015 Jan; 29(20):24-5. PubMed ID: 25585745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is IVF-served two different ways-more cost-effective than IUI with controlled ovarian hyperstimulation?
    Tjon-Kon-Fat RI; Bensdorp AJ; Bossuyt PM; Koks C; Oosterhuis GJ; Hoek A; Hompes P; Broekmans FJ; Verhoeve HR; de Bruin JP; van Golde R; Repping S; Cohlen BJ; Lambers MD; van Bommel PF; Slappendel E; Perquin D; Smeenk J; Pelinck MJ; Gianotten J; Hoozemans DA; Maas JW; Groen H; Eijkemans MJ; van der Veen F; Mol BW; van Wely M
    Hum Reprod; 2015 Oct; 30(10):2331-9. PubMed ID: 26269539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-saving treatment strategies in in vitro fertilization: a combined economic evaluation of two large randomized clinical trials comparing highly purified human menopausal gonadotropin and recombinant follicle-stimulating hormone alpha.
    Wechowski J; Connolly M; Schneider D; McEwan P; Kennedy R
    Fertil Steril; 2009 Apr; 91(4):1067-76. PubMed ID: 18339384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic implications of insurance coverage for in vitro fertilization in the United States. A review.
    Omurtag KR; Styer AK; Session D; Toth TL
    J Reprod Med; 2009; 54(11-12):661-8. PubMed ID: 20120898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Socioeconomic approach to the practice of in vitro fertilization in the Brittany region in 1993].
    Poulain P; Le Lannou D; Le Martelot MT; Vialard J; Chevalier R; Corvez A; Keraudren B; Taillanter L; Giraud JR
    Contracept Fertil Sex; 1995 Apr; 23(4):261-6. PubMed ID: 7757134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective evaluation of prognosis and cost-effectiveness of IVF in poor responders according to the Bologna criteria.
    Busnelli A; Papaleo E; Del Prato D; La Vecchia I; Iachini E; Paffoni A; Candiani M; Somigliana E
    Hum Reprod; 2015 Feb; 30(2):315-22. PubMed ID: 25432927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. All NHS bodies should offer three cycles of IVF, says NICE.
    Wise J
    BMJ; 2014 May; 348():g3344. PubMed ID: 24837736
    [No Abstract]   [Full Text] [Related]  

  • 13. In vitro fertilisation for all? Society must hear the voices of infertile people.
    Murdoch AP
    BMJ; 2003 Nov; 327(7425):1226. PubMed ID: 14630768
    [No Abstract]   [Full Text] [Related]  

  • 14. State-funded IVF will make us rich... or will it?
    Smajdor A
    J Med Ethics; 2007 Aug; 33(8):468-9. PubMed ID: 17664306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modified natural cycle versus controlled ovarian hyperstimulation IVF: a cost-effectiveness evaluation of three simulated treatment scenarios.
    Groen H; Tonch N; Simons AH; van der Veen F; Hoek A; Land JA
    Hum Reprod; 2013 Dec; 28(12):3236-46. PubMed ID: 24166594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural in vitro fertilization cycles.
    Ubaldi F; Rienzi L; Ferrero S; Baroni E; Iacobelli M; Sapienza F; Minasi MG; Cobellis L; Romano S; Scarselli F; Greco E
    Ann N Y Acad Sci; 2004 Dec; 1034():245-51. PubMed ID: 15731316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the cost-effectiveness of in vitro fertilization strategies and stimulated intrauterine insemination in a Canadian health economic model.
    Bhatt T; Baibergenova A
    J Obstet Gynaecol Can; 2008 May; 30(5):411-20. PubMed ID: 18505665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Health economic consequences of the choice of follicle stimulating hormone alternatives in IVF treatment].
    Poulsen PB; Højgaard A; Quartarolo JP
    Ugeskr Laeger; 2007 Apr; 169(14):1313-7. PubMed ID: 17437694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrauterine insemination or in-vitro fertilisation in idiopathic subfertility and male subfertility: a randomised trial and cost-effectiveness analysis.
    Goverde AJ; McDonnell J; Vermeiden JP; Schats R; Rutten FF; Schoemaker J
    Lancet; 2000 Jan; 355(9197):13-8. PubMed ID: 10615885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A survey of clinicians' views on age and access to IVF and the use of tests of ovarian reserve prior to IVF in the United Kingdom.
    Maheshwari A; Hamilton M; Bhattacharya S
    Hum Fertil (Camb); 2008 Mar; 11(1):23-7. PubMed ID: 18320436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.